Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans

Circulation

Volumn 98, Issue 1, 1998, Pages 17-24

  Diodati, Jean G ^b   Dakak, Nader ^a   Gilligan, David M ^a   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Blood flow; Endothelium; Nitric oxide; Platelets

Indexed keywords

ACETYLCHOLINE; ARGININE; COLLAGEN; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM LESION; FEMALE; FEMORAL ARTERY FLOW; HUMAN; HUMAN CELL; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0032493426     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.1.17     Document Type: Article

References (79)

1. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
2. Vanhoutte PM. The endothelium: modulator of vascular smooth muscle tone. N Engl J Med. 1988;319:512-513.
3. Palmer R, Ferrige A, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
4. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3'5'monophosphate in ADP-induced platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946-955.
5. Adrie C. Antiplatelet properties of nitric oxide. Arch Mal Coeur Vaiss. 1996;89:1527-1532.
6. Minuz P, Lechi C, Gaino S, Bonapace S, Fontana L, Garbin U, Paluani F, Cominacini L, Zatti M, Lechi A. Oxidized LDL and the reduction of the antiaggregating activity of nitric oxide derived from endothelial cells. Thromb Haemost. 1995;74:1175-1179.
7. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol. 1986;88:411-415.
8. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol. 1987;90:687-692.
9. Radomski MW, Rees DD, Dutra A, Moncada S. S-Nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992; 107:245-249.
10. Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res. 1989;65:1798-1803.
11. Bhardwaj R, Page CP, May GR, Moore PK. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Ear J Pharmacol. 1988;157:83-91.
12. Hogan JC, Lewis MJ, Henderson AH. In vivo EDRF activity influences platelet function. Br J Pharmacol. 1988;94:1020-1022.
13. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-5197.
14. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148:1482-1489.
15. Martin M, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by haemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1983;232:708-716.
16. Evans HG, Ryley HC, Hallett I, Lewis MJ. Human red blood cells inhibit endothelium-derived relaxing factor (EDRF) activity. Eur J Pharmacol. 1989;163:361-364.
17. Edwards DH, Griffith TM, Ryley HC, Henderson AH. Haptoglobin-haemoglobin complex in human plasma inhibits endothelium-dependent relaxation: evidence that endothelium-derived relaxing factor acts as a local autocoid. Cardiovasc Res. 1986;20:549-556.
18. Vallance P, Benjamin N, Collier J. The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man. Eur J Clin Pharmacol. 1992;42:37-41.
19. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-1755.
20. Quyyumi AA, Dakak N, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO III. Impaired release of nitric oxide from atherosclerotic human coronary vasculature. J Am Coll Cardiol. 1997;29:308-317.
21. Quyyumi AA. Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO III. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia; comparison of acetylcholine and substance P. Circulation. 1997;95:104-110.
22. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors or coronary artery disease. Circulation. 1990;81:491-497.
23. Egashira K, Inou T, Hirooka Y, Yamade A, Maruoka Y, Kai H, Sugimachi M, Suzuki J, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
24. Mugge A, Heublein B, Kuhn M, Nolte C, Haverich, A, Warnecke J, Forssmann W-G, Lichtlen PR. Impaired coronary dilator responses to substance P and impaired flow-dependent dilator responses in heart transplant patients with graft vasculopathy. J Am Coll Cardiol. 1993;21:163-170.
25. Nosaka S, Nakayama K, Hashimoto M, Sasaki T, Gu K, Saitoh Y, Kin S, Yamauchi M, Masumura S, Tamura K. Inhibition of platelet aggregation by endocardial endothelial cells. Life Sci. 1996;59:559-564.
26. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980;3:135-158.
27. Diodati J, Théroux P, Latour JG, Lacoste L, Lam JYT, Waters D. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol. 1990;66;683-688.
28. Diodati JG, Cannon RO, Epstein SE, Quyyumi AA. Platelet hyperaggregability across the coronary bed in response to rapid atrial pacing in patients with stable coronary artery disease. Circulation. 1992;56:1186-1193.
29. Diodati JG, Cannon RO III, Hussain N, Quyyumi AA. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am J Cardiol. 1995;75:443-448.
30. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
31. Pohl U, Nolte C, Bunse A, Eigenthaler M, Walter U. Endotheliumdependent phosphorylation of vasodilator-stimulated protein in platelets during coronary passage. Am J Physiol. 1994;266:8606-8612.
32. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995;125:370-377.
33. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995;57:2049-2055.
34. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes: characterization, purification, molecular cloning and functions. Hypertension. 1994;23:1121-1131.
35. Stamler J, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, Cooke JP, Loscalzo J. N-Acetylcysteine potentiates platelet inhibition by endothelium derived relaxing factor. Circ Res. 1989;65:789-795.
36. Yao S-K, Ober JC, Krishnaswami A, Ferguson JJ, Anderson V, Golino P, Buja LM, Willerson JT. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endotheliuminjured arteries. Circulation. 1992;86:1302-1309.
37. Lieberiman EH, O'Neil S, Mendelsohn ME. S-Nitrosocysteine inhibition of human platelet secretion is correlated with increases in cGMP levels. Circ Res. 1991;68:1722-1728.
38. Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood. 1980;55:649-654.
39. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985;766:703-708.
40. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation. 1988;78:712-716.
41. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 1988;93:515-524.
42. Moncada S. Biological importance of prostacyclin. Br J Pharmacol. 1982;76:3-31.
43. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
44. Diodati JG; Quyyumi AA, Hussain N; Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biologic release of nitric oxide: anti-platelet effect. Thromb Hemost. 1993;70:654-658.
45. Holtz J, Forstermann U, Pohl U, Giesler M, Bassenge E. Flow-dependent, endothelium-mediated dilatation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol. 1984;6:1161-1169.
46. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol. 1991;18:1529-1536.
47. Rovin JD, Stamler JS, Loscalzo J, Folts JD. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. J Cardiovasc Pharmacol, 1993;22:626-631.
48. Saxon A, Kattlove HE. Platelet inhibition by sodium nitroprusside, a smooth muscle inhibitor. Blood. 1976;47:957-961.
49. Bohme E, Graf H, Schultz G. Effects of sodium nitroprusside and other smooth muscle cell relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res. 1978;9:131-143.
50. Levin RL, Weksler BB, Jaffe EA. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation. 1982;66:1299-1307.
51. Rettkowski W, Ponicke K, Block HU, Giebier CH, Dunemann A, Zeih U, Forster W. Studies of the influence of nitroglycerin on the synthesis of prostacyclin and thromboxane A2 and on platelet aggregation. Arzneimittelforschung. 1982;32:194-200.
52. Ring T, Knudson F, Kristensen SD, Larsen CE. Nitroglycerin prolongs the bleeding time in healthy males. Thromb Res. 1983;29:553-559.
53. Mehta J, Mehta P. Comparative effect of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol. 1980;2:25-33.
54. Anfosi G, Massucco P, Mularoni E, Cavalot F, Mattiello L, Trovati M. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost. Prostaglandins Leukot Essent Fatty Acids. 1993;49:839-845.
55. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. Contribution of nitric oxide to metabolic vasodilation in the human heart. Circulation. 1995;92:320-326.
56. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325:1551-1556.
57. Gordon JB, Ganz P, Nabel EG, Fish D, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989;83:1946-1952.
58. Dakak N, Husain S, Mulcahy DM, Andrews NP, Panza JA, Waclawiw M, Schenke W, Quyyumi AA. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction and effect of L-arginine. Hypertension. In press.
59. Lamontagne D, Pohl U, Busse R. Mechanical deformation of vessel wall and shear stress determine the basal release of endothelium-derived relaxing factor in the intact rabbit coronary vascular bed. Circ Res. 1992;70:123-130.
60. Kroll MH, Hellmuns JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996;88:1525-1541.
61. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulinrequiring enzyme. Proc Natl Acad Sci U S A. 1990;685:682-685.
62. Stuehr DJ, Hearn JC, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A. 1991;88:7773-7777.
63. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-3378.
64. Arnal JF, Munzel T, Venema RC, James NL, Bai CL, Mitch WE, Harrison DG. Interactions between L-arginine and L-glutamine change endothelial NO production: an effect independent of NO symhase substrate availability. J Clin Invest. 1995;95:2565-2572.
65. Tsao PS, Singer AH, Leung LLK, Cooke JP. L-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14:1529-1533.
66. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer PS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol. 1995;26:1054-1061.
67. Wolf A, Zalpour C, Theilmeier G, Wang B-Y, Adrian M, Anderson G, Tsao PS, Cooke JP. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol. 1997;29:479-485.
68. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 1996;97:1989-1994.
69. Panza JA, Casino PR, Badar DM, Quyyumi AA, Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 1993;87:1475-1481.
70. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. 1994;23:844-850.
71. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
72. MacAllister RJ, Calver AL, Collier J, Edwards CMB, Herreros B, Nussey SS, Vallance P. Vascular and hormonal responses to arginine: provision of Substrate for nitric oxide or non-specific effect? Clin Sci. 1995;89:183-190.
73. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulinmediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.
74. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
75. Sharp DS, Beswick AD, O'Brien JR, Renaud S, Yarnell JW, Elwood PC. The association of platelet and red cell count with impedance changes in whole blood and light-scattering changes in platelet rich plasma: evidence from the Caerphilly Collaborative Heart Disease Study. Thromb Haemost. 1990;64:211-215.
76. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn P. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613-617.
77. Tanner FC, Boulanger CM, Luscher TF. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Haemost. 1993;19:167-175.
78. Ross R. Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis. 1981;1:293-311.
79. Wu KK. Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. J Formos Med Assn. 1996;95:661-666.